Carlsmed, Inc.

As of June 30, 2026, Carlsmed, Inc. carries a market capitalization of 283.04M, placing it among publicly traded companies globally. Its enterprise value stands at 215.73M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Carlsmed, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Carlsmed, Inc. has 27.27M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.17, and the price-to-book ratio stands at 3.36.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 215.73M versus a market cap of 283.04M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Carlsmed, Inc. maintains a current ratio of 8.84, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.02, indicating elevated leverage, while an interest coverage ratio of -47.00 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -42.39, reflecting losses generated across the asset base. The company generates approximately 538,680.85 in revenue per employee across its workforce of 117.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.85 indicates how many times Carlsmed, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Carlsmed, Inc.'s stock has gained approximately 5.18% over the past 52 weeks. The 50-day moving average sits at 14.99, while the 200-day moving average is 12.35.

Over the twelve months ended June 30, 2026, Carlsmed, Inc. generated 63.30M in revenue and converted that into -36.34M in net income, yielding earnings per share of -1.43. EBITDA reached -62.70M, while operating income came in at -38.66M.

As of June 30, 2026, Carlsmed, Inc. holds 89.22M in cash and equivalents against 21.92M in total debt, resulting in a net debt position of -30.86M. Total book value stands at 84.25M, with working capital of 97.20M providing operational flexibility.

Carlsmed, Inc. produced -34.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -432,000.00 in capital expenditures, free cash flow totaled -34.58M - equivalent to -1.36 per share.

Over the twelve months ended June 30, 2026, Carlsmed, Inc. posted a gross margin of 76.63, reflecting its pricing power and cost economics. The operating margin of -61.09 and net profit margin of -57.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -13.10: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -32.28, meaning Carlsmed, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Carlsmed, Inc. has an Altman Z-Score of 4.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.